Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Survodutide titration in obesity
NCT03591718Phase 1Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Jul 2018
- Primary completion
- Apr 2020
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in obesity comparing BI 456906 with Placebo (2 arms). Primary endpoint: Cumulative number of patients withdrawn from up-titration by up-titration scheme up to 132 days. Started Jul 2018; status: completed.
02
Drugs
03
Conditions
obesity
Beyond the preview
Go deeper on NCT03591718.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03591718.